|
Vaccine Detail
tyrosinase240–251S, 368-376D Vaccine |
Vaccine Information |
- Vaccine Name: tyrosinase240–251S, 368-376D Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007118
- Type: Peptide vaccine
- Status: Research
- Antigen: malaria circumsporozoite protein334–342, gp10017–25, gp100614–622
- Immunization Route: Intramuscular injection (i.m.)
- Description: This is for Melanoma Cancer (Slingluff et al., 2003).
|
Host Response |
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: T-cell responses to melanoma peptides were observed in 42% of PBLs and 80% of SINs, but in patients vaccinated with DCs, they were observed in only 11% and 13%, respectively. Helper T-cell responses to the tetanus peptide were detected in PBLs after vaccination and correlated with T-cell reactivity to the melanoma peptides (Slingluff et al., 2003).
|
References |
Slingluff et al., 2003: Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(21); 4016-4026. [PubMed: 14581425].
|
|